Terrestrial Energy is rated as a 'Buy' with a fair value target of $9 per share, suggesting an 80% upside from current levels. The company's IMSR technology uses a replaceable Core-unit and low-enriched uranium fuel, enabling recurring revenues and reducing supply chain risks. Progress in regulatory approvals, site control at Texas A&M-RELLIS, and a strong cash position help de-risk the project before major dilution. Despite being undervalued compared to peers, Terrestrial Energy shows tangible milestones and a business model poised for significant value growth.
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...
Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...
